Reuters provides insight into how South Korea turbocharged specialty syringe production

Reuters provided a deep dive into how South Korea engineered a jump in the production of low dead scale (LDS) syringes, a type of syringe designed to minimize the amount of a drug left in the device after injection. The niche products were suddenly in huge demand globally after it became apparent they could be used to squeeze out a sixth dose from vials of Pfizer Inc and BioNTech’s COVID-19 vaccine compared to five doses with a standard syringe. The country put together a strategy to tout Poonglim Pharmatech’s LDS syringes, jack up production and in doing so help Pfizer increase supply of what had just weeks earlier become the first COVID-19 shot to be approved in Britain and the United States. 

Article Tags
Topics of Interest: Health
Type: Reuters Best
Sectors: Pharmaceuticals & Healthcare
Regions: Asia
Countries: South Korea
Win Types: Storytelling
Story Types: Human Interest / Feature
Media Types: Text
Customer Impact: Important Regional Story
Sign up for email updates

Sign up for email updates